BlogZone Get the app

Finance

Insmed stock price target maintained at $195 by Mizuho on FDA review

Investing.com 22 Sept 2026 1 views

BlogZone shows headlines and summaries from public news feeds. The full story is published by Investing.com.

Read the full story at Investing.com →

Enjoyed this?

Get more stories like this — and write your own — in the BlogZone app.

Get the app

More in Finance

Pope Leo visits remote Andes town on special stop of Peru tour

Investing.com · 20 min ago

At the Supreme Court, Trump aims to cut the power of judges again

Investing.com · 38 min ago

Neostellar Capital director Mazur buys $30,500 in shares

Investing.com · 43 min ago